Edition:
United States

CEL-SCI Corp (CVM.A)

CVM.A on American Stock Exchange

1.80USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
23,723
52-wk High
$3.90
52-wk Low
$1.46

Chart for

About

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and... (more)

Overall

Beta: -1.25
Market Cap(Mil.): $25.19
Shares Outstanding(Mil.): 13.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Cel-Sci Reports Recent Data Review By The Independent Data Monitoring Committee

* CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

Dec 07 2017

BRIEF-Cel-Sci says discovered an error in accounting

* Cel-Sci Corp says ‍in November co discovered an error in way it accounted for lease for its manufacturing facility - SEC filing​

Nov 22 2017

BRIEF-Cel-Sci ‍extends expiration date of series DD and series EE warrants​

* Says ‍extended expiration date of its series dd and series ee warrants until close of business on December 1, 2017​

Aug 31 2017

BRIEF-Sabby Management reports 7.40 oct passive stake in CEL-SCI Corp

* Sabby Management LLC reports 7.40 percent passive stake in CEL-SCI Corp ‍​as of August 23 - sec filing Source text : http://bit.ly/2voxewG Further company coverage:

Aug 23 2017

BRIEF-CEL-SCI announces $3.5 mln registered direct offering

* CEL-SCI Corp - ‍intends to use net proceeds from offering for Phase 3 clinical study and general corporate purposes​

Aug 23 2017

Competitors

Earnings vs. Estimates